Abstract：Objective：To observe the clinical effect of Yigan Kangxian tang combined with entecavir for hepatitis B cirrhosis during compensatory phase. Methods：A total of 60 cases of patients with hepatitis B cirrhosis during compensatory phase were selected and divided into the control group and the observation group according to the random number table method，with 30 cases in each group. The control group was treated with entecavir，and the observation group was additionally treated with Yigan Kangxian tang based on the treatment of the control group. Both groups were treated for three months. The levels of inflammatory factors， liver function indexes and liver fibrosis indexes and the values of liver stiffness measure(LSM) before and after treatment as well as the clinical effects in the two groups were compared. Results：The total effective rate was 90.00% in the observation group，higher than that of 66.67% in the control group(P＜0.05). After treatment，the levels of interleukin-6(IL-6) and interleukin-8(IL-8) in the two groups were decreased when compared with those before treatment(P＜0.05)， and the levels of interferon-γ(INF-γ) and interleukin-10(IL-10) were increased(P＜0.05)；the levels of IL-6 and IL-8 in the observation group were lower than those in the control group(P＜0.05)，and the levels of INF-γ and IL-10 were higher(P＜0.05). After treatment，the levels of total bilirubin(TBil)，alanine aminotransferase(ALT) and aspartate aminotransferase(AST) in the two groups were decreased when compared with those before treatment(P＜0.05)，and the levels of albumin(Alb) were increased(P＜0.05)；the levels of TBil，ALT and AST in the observation group were lower than those in the control group(P＜0.05)，and the level of Alb was higher(P＜0.05). After treatment， the levels of hyaluronic acid(HA)， laminin(LN) and collagen of type Ⅳ ( Ⅳ- C) and the values of LSM in the two groups were decreased when compared with those before treatment(P＜0.05)；the levels of HA，LN and Ⅳ- C and the value of LSM in the observation group were lower than those in the control group(P＜0.05). Conclusion：The therapy of Yigan Kangxian tang combined with entecavir for hepatitis B cirrhosis during compensatory phase can effectively improve liver function， and inhibit inflammatory responses and liver fibrosis.